Intriguingly, the predictive potential of sPD-L1 at baseline as a biomarker of response to ICI therapy seems to be independent of the PD-L1 expression pattern in tumor tissues; in fact, baseline tumor PD-L1 expression has already been reported as being not correlated with ORR or OS of NIBIT-MESO-1 patients [13]. The gene discussed is CD274; the disease is neoplasm.